Q3 2025 Earnings Call Transcript October 14, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.8, ...
Despite remarkable success in relapsed or refractory B-cell malignancies, CAR T-cell therapy faces significant challenges: primary resistance, relapse, and treatment-related toxicities. This talk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback